Background: Coronavirus disease 2019 (COVID-19) can lead to acute respiratory distress
syndrome (ARDS) but it is unknown whether prone positioning improves outcomes in …

Background Myocardial injury after non-cardiac surgery (MINS) increases the risk of
cardiovascular events and deaths, which anticoagulation therapy could prevent. Dabigatran …

Background Open-label platform trials and a prospective meta-analysis suggest efficacy of
anti–interleukin (IL)-6R therapies in hospitalized patients with coronavirus disease 2019 (…

Introduction: New York City is one of the areas most affected by the COVID-19 pandemic in
the United States. Healthcare workers are among those at high risk of contracting the virus, …

Background New York City (NYC) has endured the greatest burden of COVID-19 infections
in the US. Health inequities in South Bronx predisposed this community to a greater number …

Background Tixagevimab–cilgavimab is a neutralising monoclonal antibody combination
hypothesised to improve outcomes for patients hospitalised with COVID-19. We aimed to …

Andrographolide, a diterpene lactone of the Andrographis paniculata, displays anti-HIV activity
in vitro. A series of andrographolide derivatives have been synthesized and evaluated for …

Background Sepsis remains a leading cause of death worldwide despite advances in
management strategies. Preclinical and observational studies have found mortality benefit with …

Background The open-label RECOVERY study reported improved survival in hospitalized,
SARS-CoV-2 seronegative patients treated with casirivimab and imdevimab (CAS + IMD). …

Candida species frequently cause blood stream infections and are reported to be the third
to tenth most commonly isolated pathogens. Guidelines and standardised treatment …